Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  

| More

Sanofi India - Weak quarter; sequential improvement - ICICI Securities

Posted On: 2021-02-23 23:06:11 (Time Zone: Arizona, USA)

Sanofi India's (SANL) Q4CY20's performance remained weak during the quarter. Revenue declined 12.8% YoY to Rs7.2bn but sequentially improved by 4.9%. EBITDA margin improved 160bps YoY with lower expenses but declined by 480bps QoQ to 23.2%. Adjusted PAT grew 7.4% to Rs1.2bn. As per AIOCD data, company reported a YoY growth of 3.8% for the quarter. In the past few years, the company's growth and profitability was fuelled by the power brands. We remain positive on SANL considering high visibility of strong growth from its chronic therapy exposure in domestic formulations, strong balance sheet with deep cash reserves, and strong brand equity built over the years. Maintain ADD with a revised target price of Rs8,594/share.

- Sequential improvement; costs normalising: Revenue declined 12.8% YoY, however adjusting the base for the divestment, wherein company transferred the Ankleshwar manufacturing plant and few products to Zentiva, approximate growth stood at 1.6% YoY. Company witnessed 4.9% QoQ improvement with easing of lockdown and growing patient footfalls. Costs are also normalising with raw material costs growing 12.5% QoQ suppressing gross margins by 300bps to 56.1%. While employee expenses have marginally reduced, S,G&A expenses rose by 25.2% QoQ. Overall resulting in EBITDA margin contraction of 480bps QoQ to 23.2%. On a yearly basis, transfer of the Ankleshwar plant has caused a decline in expenses resulting in 160bps jump in EBITDA margin. Company has announced a special dividend of Rs240/share in addition to Rs125/share final dividend for the year.

- Key products performance: As per AIOCD data SANL has reported a growth of 3.8% during the quarter. Lantus, Combiflam, Clexane, Avil and Targocid have reported YoY growth of 10.6%, 11.6%, 54.6%, 32.6% and 20.3% respectively for the quarter. While Allegra, Amaryl M, Cardace, Enterogermina and Amaryl have declined 16.0%, 4.9%, 4.1%, 8.5% and 4.9% YoY respectively. Higher chronic contribution (~63% of domestic sales) has supported the company in the recent uncertain environment but now demand for acute therapies is improving with easing of lockdown and that augurs well for growth.

- Outlook: We expect revenue/EBITDA/PAT to grow 6.5%/ 6.6%/10.4% over CY20-CY23E with declining export revenue contribution. We expect SANL to improve its return profile and continue generating strong free cash with growing profitability. Rising contribution of domestic revenue would help lift margins gradually.

- Valuations and risks: We reduce our revenue and EPS estimates by 1-2% and 7-8% for CY21E-CY22E to factor in lower sales and other income. Maintain ADD rating with a revised target price of Rs8,594/share based on 33xDec'22E EPS (earlier: Rs8,731/share based on 33xJun'22E). Key downside risks are: addition of key drugs in NLEM, product concentration, government intervention, and presence of unlisted promoter company.

Shares of Sanofi India Ltd was last trading in BSE at Rs.7979 as compared to the previous close of Rs. 7919.85. The total number of shares traded during the day was 5261 in over 1336 trades.

The stock hit an intraday high of Rs. 7979.65 and intraday low of 7855.35. The net turnover during the day was Rs. 41813230.

Source: Equity Bulls

Click here to send ur comments or to

Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only., its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.

Other Headlines:

Nestle India 1QCY21 results - Views by Himanshu Nayyar, Lead Analyst - Institutional Equities, YES SECURITIES

ICICI Prudential Life Insurance - Q4FY21 Result Update - YES Securities

Power: Sector Thematic - Reforms essential for renaissance - HDFC Securities

ACC 1QCY21 Results Review Report - Strong margins! - HDFC Securities

ICICI Prudential Life 4QFY21 Results Review Report - Strong micro; challenging macro - HDFC Securities

ACC Ltd - Q1CY21 Result Update - YES Securities

ICICI Prudential Life Insurance - Business momentum upwards; valuations remain attractive - ICICI Securities

Multiplex - Business disruption again - learnings and better cash position to help - ICICI Securities

ACC - Strong show led by lower costs - ICICI Securities

Brookfield India REIT - Building a strong edifice - ICICI Securities

Q4FY21 Result Preview - Oil & Gas - ICICI Direct

Q1CY21 Result Update - ACC Ltd - ICICI Direct

ACC Q1CY21 Results - Views by YES SECURITIES

Comments on Rupee from industry experts - April 19, 2021

Autos & Logistics 4QFY21 Results Preview - HDFC Securities

ADD on Mindtree - Gaining momentum - HDFC Securities

ICICI Lombard 4QFY21 Result Review - HDFC Securities

Mindtree - Q4FY21 Result Update - YES Securities

ICICI Lombard - Q4FY21 Result Update - YES Securities

HDFC Bank - Q4FY21 Result Update - YES Securities

Mindtree - Subtle downgrade in outlook! - ICICI Securities

SBI Cards and Payment Services - Play on monetisable payments growth - ICICI Securities

ICICI Lombard General Insurance Company - Cyclical recovery can protract; fundamentals remain intact - ICICI Securities

HDFC Bank - Resilience and consistency displayed to its core - ICICI Securities

Home First Finance Company - Tech-led affordable housing play at affordable valuations - ICICI Securities

Q4FY21 Result Update - Wipro Ltd - ICICI Direct

ICICI Direct - Covid Recovery Pulse - E-Way bill generation ends March 2021 on strong note...

Derivatives Strategy - Positional Future - ICICI Direct

Gladiator Stocks - Escorts - ICICI Direct

Q4FY21 Company Update - Tata Metaliks - ICICI Direct

Q4FY21 Result Update - MindTree Ltd - ICICI Direct

Q4FY21 Result Update - HDFC Bank - ICICI Direct

ICICI Direct Derivatives Weekly View (April 16): Sustainability above 14700 may trigger fresh uptrend...

Market Outlook - Technical - By Dharmesh Shah, Head - Technical, ICICIdirect

Suman Chowdhury, Chief Analytical Officer, Acuité Ratings & Research, on Monsoon outlook

ADD on Wipro - Improving growth visibility - HDFC Securities

Building Materials 4QFY21 Results Preview - Strong demand to support robust margin - HDFC Securities

Consumer Discretionary 4QFY21 Results Preview - Bargains few and far between - HDFC Securities

Consumer Durables 4QFY21 Results Preview - HDFC Securities

Wipro - Q4FY21 Result Update - YES Securities

Suman Chowdhury, Chief Analytical Officer, Acuité Ratings & Research, on March 2021 Monthly Trade Balance

Wipro - Q4FY21 Result Update - Lofty multiples leave limited margin of safety - ICICI Securities

FMCG & Alco Bev 4QFY21 Results Preview - HDFC Securities

Maintain BUY on Infosys - Q4FY21 Results Review - Buy the dip - HDFC Securities

Suman Chowdhury, Chief Analytical Officer, Acuité Ratings & Research, on March 2021 WPI Data released today

Non-leveraged financials 4QFY21 Results Preview - HDFC Securities

Infosys - A reality check! - ICICI Securities

Infosys - Q4FY21 Result Update - YES Securities

Polymer price tracker - PVC prices continue to rise - April 15, 2021 - ICICI Securities

Bharti Airtel - Restructuring aimed at digital biz, AGR-tax efficiency - ICICI Securities

Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2020